Skip to main content

Table 2 Age at diagnosis, tamoxifen use, FIGO stage, and interval between tumors, by morphology of endometrial cancer after breast cancer

From: Endometrial cancer survival after breast cancer in relation to tamoxifen treatment: Pooled results from three countries

 

Endometrial cancer morphologya

 

Endometrioid carcinomab

Serous or clear cellc

Carcinosarcomad

Sarcomae

 

N = 1,580

N = 108

N = 108

N = 54

Age at diagnosis of endometrial cancer (years)

   < 55

165

10.4

4

3.7

8

7.4

12

22.2

   55 to 64

413

26.1

19

17.6

17

15.7

15

27.8

   65 to 74

553

35.0

39

36.1

39

36.1

17

31.5

   75 to 84

363

23.0

34

31.5

33

30.6

9

16.7

   85 and over

86

5.4

12

11.1

11

10.2

1

1.9

   Mean (SD), years

68.9 (10.3)

73.4 (9.4)

71.2 (10.4)

67.6 (9.5)

 

analysis of variance (3 d.f.): P < 0.001f

Tamoxifen use

        

   Not used

651

41.2

44

40.7

19

17.6

17

31.5

   Used

929

58.8

64

59.3

89

82.4

37

68.5

 

Pearson chi-sq (3 d.f.): P < 0.0001g

   Duration of tamoxifen use among users

Used, < 2 years

272

29.3

19

29.7

11

12.4

10

27.0

2 to < 5 years

326

35.1

19

29.7

31

34.8

12

32.4

5 or more years

285

30.7

23

35.9

37

41.6

13

35.1

Used, duration unknown

46

5.0

3

4.7

10

11.2

2

5.4

Mean (SD), years

4.1 (3.2)

4.1 (2.8)

5.2 (3.3)

4.0 (2.8)

 

analysis of variance (3 d.f.): P = 0.025g

   Tamoxifen, time since last use among users

Still on/≤ 3 months

649

69.9

34

53.1

50

56.2

24

64.9

3 months to < 1 year

70

7.5

5

7.8

5

5.6

3

8.1

1 year to < 3 years

73

7.9

8

12.5

10

11.2

6

16.2

3 years to < 5 years

35

3.8

6

9.4

7

7.9

2

5.4

5 or more years

56

6.0

8

12.5

8

9.0

0

0.0

Used, time unknown

46

5.0

3

4.7

9

10.1

2

5.1

Mean (SD), years

0.8 (2.0)

1.7 (2.8)

1.3 (2.2)

0.7 (1.3)

 

analysis of variance (3 d.f.): P = 0.002g

FIGO stage

        

   I

914

57.9

46

42.6

35

32.4

21

38.9

   II

111

7.0

14

13.0

3

2.8

4

7.4

   III/IV

82

5.2

27

25.0

20

18.5

11

20.4

   Unknown

473

29.9

21

19.4

50

46.3

18

33.3

 

Peasron chi-sq (9 d.f.): P < 0.001g

Interval between breast and endometrial cancer (years)

   3 to 12 months

102

6.5

8

7.4

3

2.8

2

3.7

   1 to < 3 years

400

25.3

17

15.7

16

14.8

15

27.8

   3 to < 5 years

305

19.3

18

16.7

18

16.7

12

22.2

   5 to < 10 years

508

32.2

47

43.5

46

45.4

21

38.9

   10 to 29 years

265

16.8

18

16.7

22

20.4

4

7.4

   Mean (SD), years

5.9 (4.3)

6.5 (4.1)

6.9 (3.9)

5.2 (3.2)

 

analysis of variance (3 d.f.): (P = 0.039)g

Total

1,580

100.0

108

100.0

108

100.0

54

100.0

  1. aExcludes 25 patients where morphology was unknown; bEndometrial adenocarcinoma, mixed cell adenocarcinoma, papillary endometrial adenocarcinoma; cSerous adenocarcinoma, clear cell adenocarcinoma; dCarcinosarcoma, Mullerian mesodermal mixed tumors; eSarcoma, endometrial stromal adenocarcinoma, leiomyosarcoma; fadjusted for study; gadjusted for age at diagnosis and study. N, number; SD, standard deviation.